This is an observational study aiming at collecting efficacy and safety data on the use of SVd outside clinical trials, for the treatment of adult patients with MM who have received 1-3 prior line of therapy.
A minimum of 159 patients is required. Overall study duration is estimated in 36 months.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age equal to or greater than 18 years old at the time of SVd initiation
* Signed informed consent (if applicable).
* Diagnosis of symptomatic MM, as defined by the International Myeloma Working Group (IMWG) criteria.
* Relapse after one to three lines of therapy.
* Treatment with SVd, (i.e., having already received at least one dose) at the time the combination has entered clinical practice in Italy (AIFA authorization)
* Prior treatment with and refractoriness to lenalidomide.
Exclusion Criteria:
\- Previous exposure to selinexor.
Primary outcome measure(s)
SdV therapy effectiveness in terms of Progression Free Survival — at 12 months to describe the effectiveness of the use of SVd therapy outside clinical trials in terms of Progression free survival after 12 months from the start of treatment
Trial sites (1)
Facility
City
Region
Status
Aou Careggi - Sod Ematologia
Florence
Italy
Recruiting
More Gruppo Italiano Malattie EMatologiche dell'Adulto trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
